DK3365368T3 - Tgfbeta1-bindende immunoglobuliner og anvendelse deraf - Google Patents
Tgfbeta1-bindende immunoglobuliner og anvendelse deraf Download PDFInfo
- Publication number
- DK3365368T3 DK3365368T3 DK17716332.6T DK17716332T DK3365368T3 DK 3365368 T3 DK3365368 T3 DK 3365368T3 DK 17716332 T DK17716332 T DK 17716332T DK 3365368 T3 DK3365368 T3 DK 3365368T3
- Authority
- DK
- Denmark
- Prior art keywords
- tgfbeta1
- binding immunoglobulins
- immunoglobulins
- binding
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307353P | 2016-03-11 | 2016-03-11 | |
US201762443615P | 2017-01-06 | 2017-01-06 | |
US201762452866P | 2017-01-31 | 2017-01-31 | |
PCT/US2017/021972 WO2017156500A1 (en) | 2016-03-11 | 2017-03-10 | Tgfb1-binding immunoglobulins and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3365368T3 true DK3365368T3 (da) | 2023-06-26 |
Family
ID=58503696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17716332.6T DK3365368T3 (da) | 2016-03-11 | 2017-03-10 | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf |
Country Status (19)
Country | Link |
---|---|
US (2) | US11643459B2 (da) |
EP (2) | EP3365368B1 (da) |
JP (4) | JP2019509737A (da) |
KR (2) | KR20180122397A (da) |
CN (1) | CN109071646A (da) |
AU (2) | AU2017230103A1 (da) |
BR (1) | BR112018068340A2 (da) |
CA (1) | CA3055555A1 (da) |
DK (1) | DK3365368T3 (da) |
EA (1) | EA201891909A1 (da) |
ES (1) | ES2951648T3 (da) |
FI (1) | FI3365368T3 (da) |
HU (1) | HUE062976T2 (da) |
IL (2) | IL307835A (da) |
MX (1) | MX2018010948A (da) |
PL (1) | PL3365368T3 (da) |
PT (1) | PT3365368T (da) |
SG (1) | SG11201807176XA (da) |
WO (1) | WO2017156500A1 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3365368B1 (en) | 2016-03-11 | 2023-05-17 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
CR20190350A (es) | 2017-01-06 | 2019-11-15 | Scholar Rock Inc | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS |
CN110573161A (zh) * | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
HUE063120T2 (hu) | 2017-05-09 | 2023-12-28 | Scholar Rock Inc | LRRC33-inhibitorok és alkalmazásuk |
US20200231682A1 (en) | 2017-07-28 | 2020-07-23 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
US20210115122A1 (en) * | 2018-02-23 | 2021-04-22 | Chugai Seiyaku Kabushiki Kaisha | Cross-species anti-latent tgf-beta 1 antibodies and methods of use |
AU2019302679A1 (en) | 2018-07-11 | 2021-02-11 | Scholar Rock, Inc. | High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof |
EP3677278B1 (en) | 2018-07-11 | 2021-11-10 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
TW202019957A (zh) | 2018-07-11 | 2020-06-01 | 美商供石公司 | TGFβ1抑制劑及其用途 |
CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
MX2021009175A (es) * | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
AU2020340176A1 (en) * | 2019-08-28 | 2022-04-14 | Chugai Seiyaku Kabushiki Kaisha | Cross-species anti-latent TGF-beta 1 antibodies and methods of use |
CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
TW202135862A (zh) | 2020-01-11 | 2021-10-01 | 美商供石公司 | TGFβ抑制劑及其用途 |
EP4279509A1 (en) * | 2021-01-18 | 2023-11-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Garp protein antibody and application thereof |
JP7280400B2 (ja) * | 2021-02-26 | 2023-05-23 | 中外製薬株式会社 | 種交差性抗潜在型TGF-β1抗体の使用 |
WO2022180764A1 (en) | 2021-02-26 | 2022-09-01 | Chugai Seiyaku Kabushiki Kaisha | Uses of cross-species anti-latent tgf-beta 1 antibodies |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022206753A1 (zh) * | 2021-03-29 | 2022-10-06 | 山东先声生物制药有限公司 | GARP/TGFβ1抗体及其应用 |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
WO2023192895A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5262319A (en) | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
CN1451043A (zh) | 2000-06-29 | 2003-10-22 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
GB0230202D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
JP4653660B2 (ja) * | 2003-09-04 | 2011-03-16 | 独立行政法人理化学研究所 | TGF−β活性化制御領域の切断面を認識する抗体 |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
LT1850873T (lt) * | 2005-02-08 | 2019-04-10 | Genzyme Corporation | Antikūnas prieš tgf beta |
RS51845B (en) * | 2005-04-22 | 2012-02-29 | Eli Lilly And Company | SPECIFIC TGF BETA 1 ANTIBODIES |
EP3524626A1 (en) | 2007-03-22 | 2019-08-14 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
MX2010013236A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
TWI531377B (zh) | 2011-02-08 | 2016-05-01 | 艾伯維有限公司 | 骨關節炎及疼痛之治療 |
KR102046666B1 (ko) | 2011-05-25 | 2019-11-19 | 이나뜨 파르마 | 염증성 장애의 치료를 위한 항-kir 항체 |
EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
RU2708977C2 (ru) | 2011-06-10 | 2019-12-12 | МЕДИММЬЮН, ЭлЭлСи | Молекулы, связывающиеся с psl pseudomonas, и пути их применения |
EP2766033B1 (en) | 2011-10-14 | 2019-11-20 | Novartis AG | Antibodies and methods for wnt pathway-related diseases |
CA2856149A1 (en) | 2011-11-08 | 2013-05-16 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-m-csf antibodies |
RS56796B1 (sr) | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
US9518112B2 (en) | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
CA2890733A1 (en) | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
CN105283196B (zh) | 2013-03-15 | 2018-10-12 | 贝丝以色列女执事医疗中心 | 用于产生和使用构象-特异性抗体的方法和组合物 |
WO2014182676A2 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
MX2016001356A (es) * | 2013-08-01 | 2016-10-26 | Ludwig Inst For Cancer Res Ltd | Proteina anti-garp y sus usos. |
EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
CA2947967A1 (en) | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
ES2843277T3 (es) | 2014-06-26 | 2021-07-16 | Heidelberg Immunotherapeutics Gmbh | Aplicación tópica para un anticuerpo anti-VHS |
WO2016079157A1 (en) | 2014-11-18 | 2016-05-26 | Institut Pasteur | Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis |
CA2973978A1 (en) | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體 |
EP3365368B1 (en) * | 2016-03-11 | 2023-05-17 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
EP3484499A4 (en) | 2016-07-14 | 2020-05-13 | Scholar Rock, Inc. | ANTI-TGFB ANTIBODIES, METHODS AND USES |
CR20190350A (es) | 2017-01-06 | 2019-11-15 | Scholar Rock Inc | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS |
-
2017
- 2017-03-10 EP EP17716332.6A patent/EP3365368B1/en active Active
- 2017-03-10 BR BR112018068340A patent/BR112018068340A2/pt unknown
- 2017-03-10 PT PT177163326T patent/PT3365368T/pt unknown
- 2017-03-10 DK DK17716332.6T patent/DK3365368T3/da active
- 2017-03-10 ES ES17716332T patent/ES2951648T3/es active Active
- 2017-03-10 JP JP2018547346A patent/JP2019509737A/ja not_active Withdrawn
- 2017-03-10 CA CA3055555A patent/CA3055555A1/en active Pending
- 2017-03-10 KR KR1020187028835A patent/KR20180122397A/ko not_active Application Discontinuation
- 2017-03-10 EA EA201891909A patent/EA201891909A1/ru unknown
- 2017-03-10 MX MX2018010948A patent/MX2018010948A/es unknown
- 2017-03-10 FI FIEP17716332.6T patent/FI3365368T3/fi active
- 2017-03-10 HU HUE17716332A patent/HUE062976T2/hu unknown
- 2017-03-10 PL PL17716332.6T patent/PL3365368T3/pl unknown
- 2017-03-10 US US16/083,637 patent/US11643459B2/en active Active
- 2017-03-10 AU AU2017230103A patent/AU2017230103A1/en not_active Abandoned
- 2017-03-10 SG SG11201807176XA patent/SG11201807176XA/en unknown
- 2017-03-10 CN CN201780023887.8A patent/CN109071646A/zh active Pending
- 2017-03-10 EP EP22195559.4A patent/EP4169942A1/en active Pending
- 2017-03-10 IL IL307835A patent/IL307835A/en unknown
- 2017-03-10 KR KR1020237018780A patent/KR20230088508A/ko not_active Application Discontinuation
- 2017-03-10 WO PCT/US2017/021972 patent/WO2017156500A1/en active Application Filing
-
2018
- 2018-08-29 IL IL261442A patent/IL261442A/en unknown
-
2021
- 2021-10-26 JP JP2021174552A patent/JP2022028680A/ja not_active Withdrawn
- 2021-12-23 JP JP2021209374A patent/JP2022031403A/ja active Pending
-
2023
- 2023-03-31 US US18/193,979 patent/US20230348583A1/en active Pending
- 2023-06-19 JP JP2023100034A patent/JP2023108057A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202692A patent/AU2024202692A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FI3365368T3 (fi) | 2023-06-13 |
CA3055555A1 (en) | 2017-09-14 |
WO2017156500A8 (en) | 2018-01-25 |
US20190071493A1 (en) | 2019-03-07 |
SG11201807176XA (en) | 2018-09-27 |
WO2017156500A1 (en) | 2017-09-14 |
AU2017230103A1 (en) | 2018-09-06 |
EP4169942A1 (en) | 2023-04-26 |
US11643459B2 (en) | 2023-05-09 |
AU2024202692A1 (en) | 2024-05-30 |
US20230348583A1 (en) | 2023-11-02 |
JP2022031403A (ja) | 2022-02-18 |
CN109071646A (zh) | 2018-12-21 |
BR112018068340A2 (pt) | 2019-01-15 |
IL261442A (en) | 2018-10-31 |
KR20180122397A (ko) | 2018-11-12 |
JP2019509737A (ja) | 2019-04-11 |
MX2018010948A (es) | 2019-06-20 |
IL307835A (en) | 2023-12-01 |
JP2023108057A (ja) | 2023-08-03 |
ES2951648T3 (es) | 2023-10-24 |
HUE062976T2 (hu) | 2023-12-28 |
EP3365368B1 (en) | 2023-05-17 |
PT3365368T (pt) | 2023-08-17 |
EA201891909A1 (ru) | 2019-02-28 |
PL3365368T3 (pl) | 2023-08-21 |
JP2022028680A (ja) | 2022-02-16 |
EP3365368A1 (en) | 2018-08-29 |
KR20230088508A (ko) | 2023-06-19 |
WO2017156500A9 (en) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3258951T3 (da) | Anti-pvrig antistoffer og fremgangsmåder for anvendelse | |
DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3480213T3 (da) | Syntac-polypeptider og anvendelser deraf | |
DK3463435T3 (da) | Alpha-synuklein-antistoffer og anvendelser deraf | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3445785T3 (da) | Humaniserede anti-clever-1-antistoffer og anvendelse deraf | |
DK3359563T3 (da) | Antigenreceptorer og anvendelser deraf | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
MA49905A (fr) | Polyesteramines et polyesterquats | |
DK3448419T3 (da) | Interferon-beta-antistoffer og anvendelser deraf | |
DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf |